Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU CHMP Opinions and MAA Updates

Executive Summary

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

You may also be interested in...



Sanofi Genzyme’s Treatment For Pompe Disease On Track For EU Approval

EU reviewers have recommended marketing approval for two new medicines, but have turned down another product. 

Roche Among EU Fast-Track Hopefuls With Lymphoma Bispecific Mosunetuzumab

Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.

Amgen Strikes Early-Access Deal In England For Lung Cancer Drug Lumakras

Patients in England with non-small cell lung cancer will be the first In Europe to be offered Amgen’s KRAS G12C inhibitor.

Topics

UsernamePublicRestriction

Register

PS144706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel